Organoids Derived From Induced-Pluripotent Stem Cells (iPS) From Patients With High Grade Astrocytoma (GLIOMANOID)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03971812|
Recruitment Status : Recruiting
First Posted : June 3, 2019
Last Update Posted : June 13, 2019
The objective of this study research proposal is to model human gliomagenesis using 3-Dimensional (3D) brain organoids derived from human induced pluripotent stem cells (hiPSCs).
The working hypothesis is that 3D brain organoids can develop glioma-like structures and recapitulate phenotypic traits of gliomas when generated from hiPSCs expressing genetic mutants associated with glioma predisposition.
Methodology : To develop this pioneer study on the use of hiPSC-based brain organoids as a strategy to model gliomagenesis and study the impact of genetic mutants, it will be collect the peripheral blood mononuclear cell from 20 patients with high grade astrocytoma with or without IDH mutation. iPS will be generated from these PBMC and will be genetically modified according to different mutations. Then, it will be generate brain organoids according to standard protocols. Brain organoids generated from all different cells will be collected at different time points and analyzed for the presence of glioma-like structures and phenotypic hallmarks of gliomas.
From the proposed experiments, it will be expect that brain organoids will develop glioma-like features upon the presence of genetic mutations. Thus, it will be expect to demonstrate that brain organoids can be used as a reliable strategy to test the impact of genetic mutants, including the possible synergistic cooperation between different mutations on early gliomagenic events.
|Condition or disease||Intervention/treatment|
|Glioma||Biological: Blood sample|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Organoids Derived From Induced-Pluripotent Stem Cells (iPS) From Patients|
|Estimated Study Start Date :||June 7, 2019|
|Estimated Primary Completion Date :||December 6, 2020|
|Estimated Study Completion Date :||December 6, 2020|
Patient with high grade astrocytoma
Patients meeting inclusion and non-inclusion criteria and having signed informed consent will be included in the study
Biological: Blood sample
A blood sample of two 10 mL ethylenediaminetetraacetic (EDTA) tubes will be taken at the time of the visit. This sample will be centrifuged for isolation of peripheral blood mononuclear cells (PBMC).
- Characterize the level of proliferation of organoids [ Time Frame: 18 months ]compare different immunohistochemical markings between organoids
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03971812
|Contact: Emeline TABOURET, PH||491385500 ext +firstname.lastname@example.org|
|Contact: Dominique FIGARELLA, PUPH||413429011 ext +email@example.com|
|Assistance Publique Hôpitaux de Marseille||Recruiting|
|Marseille, France, 13354|
|Contact: Emeline TABOURET, PH 491385500 ext +33 firstname.lastname@example.org|
|Principal Investigator: Emeline TABOURET|
|Study Director:||Jean-Olivier ARNAUD, Director||Assistance Publique Hôpitaux de Marseille|